* NeuroBo Pharmaceuticals Inc reported a quarterly adjusted loss of $1.85​​ per share for the quarter ended in June, lower than the same quarter last year, when the company reported EPS of -16 cents. The mean expectation of three analysts for the quarter was for a loss of $1.12 per share. Wall Street expected results to range from $-1.46 to -53 cents per share.

* Reported revenue was zero​; analysts expected zero.

* NeuroBo Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.85​.

* The company reported a quarterly loss of $10.05 million.

* NeuroBo Pharmaceuticals Inc shares had fallen by 21.9% this quarter and gained 2.3% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 24.6% in the last three months.​

* In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for NeuroBo Pharmaceuticals Inc is $25.00 This summary was machine generated from LSEG data August 14 at 02:13 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Jun. 30 2024 -1.12 -1.85 Missed

Mar. 31 2024 -3.63 -1.32 Beat

Dec. 31 2023 -0.78 -2.28 Missed

Sep. 30 2023 -0.86 -0.72 Beat